Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Weger, W; Kränke, B; Gerger, A; Salmhofer, W; Aberer, E.
Occurrence of subacute cutaneous lupus erythematosus after treatment with fluorouracil and capecitabine.
J Am Acad Dermatol. 2008; 59(2 Suppl 1):S4-S6 Doi: 10.1016/j.jaad.2007.06.040 (- Case Report)
Web of Science PubMed FullText FullText_MUG

 

Führende Autor*innen der Med Uni Graz
Kränke Birger
Weger Wolfgang
Co-Autor*innen der Med Uni Graz
Aberer Elisabeth
Gerger Armin
Salmhofer Wolfgang
Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:
Capecitabine, an oral fluoropyrimidine and 5-fluorouracil (FU) prodrug recently approved for the treatment of metastatic colon and breast cancer, is currently under investigation in patients with gastric cancer. It has the advantage of oral administration, and good tolerability with its activity being comparable with intravenous 5-FU. Lupus erythematosus and lupuslike drug eruptions have been observed after 5-FU treatment, but so far no cases of subacute cutaneous lupus erythematosus have been described in patients treated either with capecitabine or 5-FU. We report a patient who developed subacute cutaneous lupus erythematosus after administration of 5-FU and capecitabine.
Find related publications in this database (using NLM MeSH Indexing)
Acute Disease -
Administration, Oral -
Aged -
Antimetabolites, Antineoplastic - administration & dosage Antimetabolites, Antineoplastic - adverse effects
Deoxycytidine - administration & dosage Deoxycytidine - adverse effects Deoxycytidine - analogs & derivatives
Fatal Outcome -
Female -
Fluorouracil - administration & dosage Fluorouracil - adverse effects Fluorouracil - analogs & derivatives
Humans -
Lupus Erythematosus, Cutaneous - chemically induced Lupus Erythematosus, Cutaneous - drug therapy
Severity of Illness Index -
Steroids - therapeutic use
Stomach Neoplasms - drug therapy

© Med Uni Graz Impressum